Group B streptococcus in the Northern Territory in 2023: clindamycin down but not out.
Journal
Communicable diseases intelligence (2018)
ISSN: 2209-6051
Titre abrégé: Commun Dis Intell (2018)
Pays: Australia
ID NLM: 101735394
Informations de publication
Date de publication:
21 09 2023
21 09 2023
Historique:
received:
13
09
2023
medline:
12
10
2023
pubmed:
11
10
2023
entrez:
11
10
2023
Statut:
epublish
Résumé
Group B streptococcus (GBS) is a significant cause of perinatal morbidity and mortality; prophylactic antibiotics in the obstetric population can mitigate the risk of neonatal infection. The antibiotic of choice is penicillin; however, in women who have a penicillin hypersensitivity, clindamycin is the preferred agent. Worldwide resistance to clindamycin is rising in GBS isolates. In the Top End of the Northern Territory of Australia, we reviewed 113 GBS isolates in 2023. These GBS isolates revealed a 30% resistance to clindamycin. This rate has considerably increased since the Australia-wide survey published in 2011 where GBS resistance to clindamycin was quoted at 4.2%. As a result of this study, we are advocating for a change in practice in patients with known GBS resistance with penicillin hypersensitivity.
Identifiants
pubmed: 37817335
doi: 10.33321/cdi.2023.47.52
doi:
Substances chimiques
Anti-Bacterial Agents
0
Clindamycin
3U02EL437C
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Commonwealth of Australia CC BY-NC-ND